Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Competitive Intelligence Gets a Boost with Reaxys Patent Expansion

Posted on April 30th, 2021 by

The insights only found in patents can provide a crucial competitive advantage for innovative companies. In response to customer demand, Elsevier recently announced a major expansion of the patent content available to users of Reaxys, our chemistry information solution. Users can now get relevant patents for pharma and chemical R&D from 105 patent offices and 170 IPC classes. This also includes English language translations of foreign-language patents, which is important given that scientific advances are being made every day all across the globe.

(more…)

Beyond Reference Management: How Literature Management is a Win for the Life Science Organization

Posted on April 7th, 2021 by

Scientific literature is a critical component to virtually all aspects of a life science enterprise, including Medical Affairs, Pharmacovigilance and R&D. However, the process of curating and sharing literature can lead to significant challenges in organizing content, facilitating collaboration and enforcing copyright compliance.

(more…)

FDA Introduces Data Modernization Action Plan

Posted on March 29th, 2021 by

One of the frustrations of our Big Data era is that, despite the existence of an ever-growing wealth of valuable data, this data is often stuck in different silos. This lack of accessibility makes it hard to get the most out of data that has the potential to be extremely useful.

(more…)

Harris Poll Finds Large Boost in Pharma Industry Reputation

Posted on March 15th, 2021 by

As the COVID-19 vaccine roll-out gains in intensity, it has become common to hear people toss out the names of pharmaceutical companies like Pfizer, Moderna and AstraZeneca with the same ease that they refer to their favorite brands of ketchup or peanut butter. This isn’t typical. While direct-to-consumer advertising has perhaps increased some awareness of drug makers, the pandemic has made pharma R&D a subject of public interest in an unprecedented fashion.

(more…)

  1. 1
  2. 2
  3. 3
  4. 88